ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023
Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysis.Clinical drug investigation · 2025Pooled it
- Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.Targeted oncology · 2025Trial
- Review
- Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/ refractory multiple myeloma treated in Europe.Haematologica · 2026Article
- Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody-Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization.Pharmaceutical research · 2026Review
- Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations.Drug design, development and therapy · 2026Review
- Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review.Frontiers in immunology · 2026Review
- Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin.Journal of pharmacokinetics and pharmacodynamics · 2025Article
- Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors.Antibody therapeutics · 2025Review
- A Review on Recent Trends in Photo-Drug Efficiency of Advanced Biomaterials in Photodynamic Therapy of Cancer.Mini reviews in medicinal chemistry · 2025Review
- Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies.The oncologist · 2024Review
- Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives.Medical oncology (Northwood, London, England) · 2024Review
- Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Drug-Related Keratitis: A Real-World FDA Adverse Event Reporting System Database Study.Translational vision science & technology · 2024Article
- Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.Biomedicines · 2024Article
- Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.Current treatment options in oncology · 2024Review
- Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer.American journal of ophthalmology case reports · 2024Article
- Advancements in Nanogels for Enhanced Ocular Drug Delivery: Cutting-Edge Strategies to Overcome Eye Barriers.Gels (Basel, Switzerland) · 2023Review
- A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Antibody-drug conjugates consist of a monoclonal antibody attached to a cytotoxic therapeutic molecule by a connector. This association allows a highly specific therapy, which increases their effectiveness and decreases their potential toxicity. This new therapy emerged approximately 20 years ago; since then, numerous combinations have appeared in the field of treatment-related neoplasms as an alternative for patients who do not achieve good results with conventional treatment options. Adverse effects of these drugs on the ocular surface are frequent and varied. Their prevalence ranges from 20 to 90% depending on the drug and administration condition, probably due to multiple receptor-mediated factors or mechanisms not mediated by specific receptors, such as macropinocytosis. These adverse events can greatly limit patients' comfort; thus, the objectives of this article were, in the first place, to compile the information currently available on different types of adverse effects of antibody-drug conjugates on the ocular surface, including pathophysiology, prevalence, and treatment, and in second place, to contribute to the correct identification and management of these events, which will result in a lower rate of cessation of treatment, which is necessary for the survival of candidate patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.